Last reviewed · How we verify
Standard treatment with benznidazole
Benznidazole is an antiparasitic drug that works by inhibiting the growth of the parasite Trypanosoma cruzi.
Benznidazole is an antiparasitic drug that works by inhibiting the growth of the parasite Trypanosoma cruzi. Used for Chagas disease.
At a glance
| Generic name | Standard treatment with benznidazole |
|---|---|
| Also known as | Benznidazole 8 weeks |
| Sponsor | Laboratorio Elea Phoenix S.A. |
| Drug class | nitroimidazole |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Benznidazole is a nitroimidazole derivative that is activated by the parasite's cellular enzymes, leading to the formation of reactive intermediates that damage the parasite's DNA and inhibit its growth. This results in the death of the parasite and the resolution of the infection.
Approved indications
- Chagas disease
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Key clinical trials
- Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age (PHASE3)
- Short Benznidazole Regimen for Chronic Phase Chagas Disease Patients (PHASE3)
- Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease (PHASE3)
- Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: